Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study
Abstract
Abstract Background: Data on outcomes and prognostic factors in older adults with Hodgkin lymphoma (HL) from Latin America remain scarce. We aimed to characterize overall survival (OS) and identify clinical predictors of 5-year OS in this population. Methods: We analyzed a multicenter cohort of 241 HL patients, treated with ABVD regimen, aged ≥60 years from Latin America. Clinical, laboratory, and treatment variables were harmonized and cleaned for analysis. Five-year OS was estimated using Kaplan-Meier methods. Univariate Cox regression models tested associations between OS and covariates including age, Ann Arbor stage, lymphocyte count, hemoglobin, and PET response. Variables significant in univariate analyses and clinically relevant were included in a multivariable Cox proportional hazards model. Results: Median age was 68 years (range 60–88), with 61% males. The 5-year OS was 65.2% (95% CI: 58.0–73.3%). In univariate analysis, increasing age (HR per year 1.06, p=0.0018), advanced Ann Arbor stage, lymphopenia (<600/mm³ or <8%; HR=0.43, p=0.007), and anemia (Hb <10 g/dL; HR=0.40, p=0.001) were significantly associated with worse OS. PET response was not significantly associated with OS. In the multivariable model (n=154, 38 events), older age (HR 1.08 per year, p=0.0007), advanced Ann Arbor stage (notably stages IIA, IIIA, IIIB; p<0.05), and lymphopenia (HR 0.39, p=0.023) remained independent predictors of inferior 5-year OS. Hemoglobin was not independently significant after adjustment. Conclusions: Older age, advanced disease stage, and low lymphocyte count independently predict poorer survival in older Latin American patients with HL. These factors should be incorporated into risk stratification and management decisions to improve outcomes. Further research is needed to optimize therapies tailored for this population. Keywords: Hodgkin lymphoma, elderly, Latin America, survival, prognostic factors
Article Details
Authors (24)
Amy Alvarenga Tanii
1Instituto de Previsión social, Asunción, Paraguay
Alana von Glasenapp
10Instituto de Previsión Social, Asunción, Paraguay
Sofía Rivarola
13Hospital Británico de Buenos Aires, Buenos Aires, Argentina
German Stemmelin
8Hospital Británico de Buenos Aires, Buenos Aires, Argentina
Ana Oliver
4CASMU, Montevideo, Uruguay
Victoria Irigoin
6British Hospital, Montevideo, Uruguay/ CASMU, Montevideo, Uruguay, Montevideo, Uruguay
Virginia Lema Spinelli
4Servicio medico Integral, Montevideo, Uruguay
Maria Enciso Arrua
1Instituto de Prevision Social, Hematology, Asuncion, Paraguay
Julio Fernández-Águila
5Gustavo Aldereguía University Hospital, Cienfuegos, Cuba
Rosa Rios Jimenez
7Hospital Dr Luis Díaz Soto, Cuba, Habana, Cuba
Fernando Warley
9Universidad del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Maria Orlova
9Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Jule Vasquez
11Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
miguel Nicolas lopez Caceres
9Clínica Alemana, Santiago, Chile
Alfredo Quiroz
14Hospital Central IPS, Asuncion, Paraguay
Denisse Castro
6Hospital Edgardo Rebagliati, Lima, Peru
Marialejandra Torres Viera
15Clinica Santa Sofia, Caracas, Venezuela
Henry Quintero
12Universidad Tecnológica de Pereira, Pereira, Colombia
Luis Mario Villela Martinez
16Hospital Fernando Ocaranza, Hermosillo, Mexico
Javier Retamales
14Grupo Oncológico Cooperativo Chileno de Investigación (GOCCHI), Santiago, Chile
Bryan Valcarcel
Brady Beltran
6Hospital Edgardo Rebagliati, Lima, Peru
Jorge Castillo
1Dana-Farber Cancer Institute, Bing Center for Waldenstrom's Macroglobulinemia, Boston, United States
Luis Malpica